Edition:
United States

argenx NV (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

80.50USD
23 Feb 2018
Change (% chg)

$-0.77 (-0.95%)
Prev Close
$81.27
Open
$80.59
Day's High
$81.52
Day's Low
$79.42
Volume
32,215
Avg. Vol
52,320
52-wk High
$87.00
52-wk Low
$17.42

Chart for

About

argenx NV, formerly arGEN X BV is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused... (more)

Overall

Beta: 0.56
Market Cap(Mil.): €2,091.10
Shares Outstanding(Mil.): 32.17
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Argenx Announces Updated Size Of Proposed Public Offering In The U.S. To 3.5 Million ADSS

* HAS UPDATED NUMBER OF AMERICAN DEPOSITARY SHARES ("ADSS") IN ITS UNDERWRITTEN U.S. PUBLIC OFFERING (OFFERING) TO 3.5 MILLION ADSS

Dec 13 2017

BRIEF-Argenx announces launch of proposed public offering in United States

* ARGENX ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING IN THE UNITED STATES

Dec 11 2017

BRIEF-Argenx Files For Offering Of Up To $150 Mln American Depositary Shares

* ARGENX FILES FOR OFFERING OF UPTO $150.0 MILLION OF AMERICAN DEPOSITARY SHARES - SEC FILING Source text: (http://bit.ly/2kmUxUi) Further company coverage:

Dec 11 2017

BRIEF-Argenx To Provide Updates On Phase 1/2 Clinical Trials Of ARGX-110

* TO PROVIDE UPDATES ON PHASE 1/2 CLINICAL TRIALS OF ARGX-110 IN ACUTE MYELOID LEUKEMIA AND CUTANEOUS T-CELL LYMPHOMA DURING AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Dec 11 2017

BRIEF-Argenx Reports Positive Topline Results From Phase 2 Trial Of ARGX-113

* REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF ARGX-113

Dec 11 2017

BRIEF-Argenx launches phase I trial with subcutaneous formulation of ARGX-113​

* ‍ARGENX LAUNCHES PHASE I TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113​

Oct 30 2017

BRIEF-Argenx 9M total comprehensive loss widens to 16.5 million euros

* REG-ARGENX REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Oct 26 2017

BRIEF-ArgenX launches Phase II proof-of-concept clinical trial of ARGX-113 for treatment of pemphigus vulgaris

* ARGENX LAUNCHES PHASE II PROOF-OF-CONCEPT CLINICAL TRIAL OF ARGX-113 FOR THE TREATMENT OF PEMPHIGUS VULGARIS

Sep 26 2017

BRIEF-Argenx reaches 50% enrollment in phase 2 clinical trial of ARGX-113

* REG-ARGENX REACHES 50% ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF ARGX-113 IN IMMUNE THROMBOCYTOPENIA

Sep 20 2017

Earnings vs. Estimates